Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 24-Week, Multicenter, Randomized, Open-Label, Parallel-Group Trial Comparing the Efficacy and Safety of Insulin Glargine 300 U/mL (Gla-300) and Insulin Degludec 100 U/mL (IDeg-100) in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment: TRENT Trial

NCT05552859 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT05552859
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05552859 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 24-Week, Multicenter, Randomized, Open-Label, Parallel-Group Trial Comparing the Efficacy and Safety of Insulin Glargine 300 U/mL (Gla-300) and Insulin Degludec 100 U/mL (IDeg-100) in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment: TRENT Trial
Lead sponsor
Sanofi
Phase
Phase 4
Overall status
Terminated
Start date
December 5, 2022
Completion date
August 4, 2023
Enrollment
62 (actual)
Sites
68

Conditions

As the registry lists them; a condition with its own page is linked.

renal impairment, type 2 diabetes mellitus